吉非替尼耐药的晚期非小细胞肺癌联合重组人血管内皮抑素解救治疗的临床研究

王慧娟; 张国伟; 王启鸣; 朱辉; 李鹏; 闫相涛; 李少梅; 马智勇

吉非替尼耐药的晚期非小细胞肺癌联合重组人血管内皮抑素解救治疗的临床研究

河南省肿瘤医院内科,河南郑州,450003

基金项目: 中国高校医学期刊临床专项资金

详细信息

中图分类号: R734.2
计量
- 文章访问数: 132
- HTML全文浏览量: 30
- PDF下载量: 6
出版历程
- 发布日期: 2013-02-27

Clinical study on the relief treatment of the combined recombinant human endostatin after failed treatment of gefitinib for advanced non-small cell lung cancer

摘要

摘要: 目的探讨晚期非小细胞肺癌(NSCLC)患者吉非替尼治疗失败后,联合恩度解救治疗的疗效和生存.方法确定为吉非替尼治疗失败的晚期NSCLC患者接受联合恩度治疗,具体用法:恩度15 mg/d,连续静脉输注1d,休息7 d,21 d/周期.观察患者联合治疗的疗效,生存和毒性结果.结果 1例获得部分缓解(PR)(10％),6例稳定(SD)(60％),3例进展(PD)(30％)；客观缓解率(ORR)为10％,疾病控制率(DCR)为70％；联合治疗后的中位PFS为4.2个月(95％CI:3.21个月～5.19个月)；联合治疗开始后的中位OS是8个月(95％CI:4.96个月～11.04个月).DCR、PFS和OS与患者的性别、年龄、PS评分、病理类型及易瑞沙服药时间长短均无相关性.结论吉非替尼治疗失败后联合恩度解救治疗可使部分患者疾病获得稳定,延长生存时间,并且毒性可以耐受,可以扩大样本量进行深入研究.
- 非小细胞肺癌 /
- 表皮生长因子受体 /
- 吉非替尼 /
- 重组人血管内皮抑素 /
- 耐药

HTML全文

参考文献(10)

王慧娟, 王启呜, 张国伟. 重组人血管内皮抑制素联合含铂方案一线治疗晚期非小细胞肺癌的临床疗效 [J]. 肿瘤, 2011(3):264.doi: 10.3781/j.issn.1000-7431.2011.03.015.

朱辉, 张国伟, 王慧娟. 恩度联合NP或GP方案一线治疗晚期非小细胞肺癌疗效比较 [J]. 医药论坛杂志, 2011(2):59.

Ciardiello F, Tortora G. EGFR antagonists in cancer treatment [J]. New England Journal of Medicine, 2008, (11):1160.

Mok T S, Wu Y L, Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. New England Journal of Medicine, 2009, (10):947.

Sjoblom T, Jones S, Wood L D. The consensus coding sequences of human breast and colorectal cancers [J]. Science, 2006, (5797):268.

Oxnard G R, Arcila M E, Chmielecki J. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer [J]. Clinical Cancer Research, 2011, (17):5530.

J.R.Brahmer R G, J.H.Schiller MP. Johnson ASaD.ECOG 4599 phase Ⅲ trial of carboplatin and paclitaxel ± bevacizumab:Subset analysis of survival by gender [J]. Journal of Clinical Oncology, 2006, (18S (June 20 Supplement):7036.

Herbst R S, O'Neill V J, Fehrenbacher L. Phase Ⅱ study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer [J]. Journal of Clinical Oncology, 2007, (30):4743.

Herbst R S, Ansari R, Bustin F. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa):a double blind, placebo-controlled, phase 3 trial [J]. The Lancet, 2011, (9780):1846.

Naumov G N, Nilsson M B, Cascone T. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor reaistance [J]. Clinical Cancer Research, 2009, (10):3484.

施引文献

资源附件(0)

计量

文章访问数: 132
HTML全文浏览量: 30
PDF下载量: 6
被引次数: 0

吉非替尼耐药的晚期非小细胞肺癌联合重组人血管内皮抑素解救治疗的临床研究

计量

出版历程

Clinical study on the relief treatment of the combined recombinant human endostatin after failed treatment of gefitinib for advanced non-small cell lung cancer

计量

出版历程

目录